Eli Lilly's First Biotech Deal Of 2024, Buys Chronic Disease Player Morphic For $3.2BBenzinga • 07/08/24
GordonMD® Global Investments Portfolio Company, Radionetics Oncology, Announced Strategic Agreement with LillyBusiness Wire • 07/08/24
Lilly to Acquire Morphic to Improve Outcomes for Patients with Inflammatory Bowel DiseasePRNewsWire • 07/08/24
Mounjaro and Zepbound Are Great, but This Is the Real Reason Why Eli Lilly Can Soar Past a $1 Trillion ValuationThe Motley Fool • 07/04/24
Novo Nordisk, Eli Lilly Tumble After Study Suggests Weight-Loss Drugs Can Lead To BlindnessInvestors Business Daily • 07/03/24
Eli Lilly's Alzheimer's Therapy's Broad Label Reflects Regulatory Confidence in Anti-Amyloid Antibodies: AnalystBenzinga • 07/03/24